Literature DB >> 33588951

Emergence of nosocomial associated opportunistic pathogens in the gut microbiome after antibiotic treatment.

Isaac Raplee1, Lacey Walker1, Lei Xu1, Anil Surathu1, Ashok Chockalingam1, Sharron Stewart1, Xiaomei Han1, Rodney Rouse1, Zhihua Li2.   

Abstract

INTRODUCTION: According to the Centers for Disease Control's 2015 Hospital Acquired Infection Hospital Prevalence Survey, 1 in 31 hospital patients was infected with at least one nosocomial pathogen while being treated for unrelated issues. Many studies associate antibiotic administration with nosocomial infection occurrence. However, to our knowledge, there is little to no direct evidence of antibiotic administration selecting for nosocomial opportunistic pathogens. AIM: This study aims to confirm gut microbiota shifts in an animal model of antibiotic treatment to determine whether antibiotic use favors pathogenic bacteria.
METHODOLOGY: We utilized next-generation sequencing and in-house metagenomic assembly and taxonomic assignment pipelines on the fecal microbiota of a urinary tract infection mouse model with and without antibiotic treatment.
RESULTS: Antibiotic therapy decreased the number of detectable species of bacteria by at least 20-fold. Furthermore, the gut microbiota of antibiotic treated mice had a significant increase of opportunistic pathogens that have been implicated in nosocomial infections, like Acinetobacter calcoaceticus/baumannii complex, Chlamydia abortus, Bacteroides fragilis, and Bacteroides thetaiotaomicron. Moreover, antibiotic treatment selected for antibiotic resistant gene enriched subpopulations for many of these opportunistic pathogens.
CONCLUSIONS: Oral antibiotic therapy may select for common opportunistic pathogens responsible for nosocomial infections. In this study opportunistic pathogens present after antibiotic therapy harbored more antibiotic resistant genes than populations of opportunistic pathogens before treatment. Our results demonstrate the effects of antibiotic therapy on induced dysbiosis and expansion of opportunistic pathogen populations and antibiotic resistant subpopulations of those pathogens. Follow-up studies with larger samples sizes and potentially controlled clinical investigations should be performed to confirm our findings.

Entities:  

Keywords:  Antibiotic resistance; Antibiotic therapy; Metagenomics; Microbiota; Nosocomial

Year:  2021        PMID: 33588951      PMCID: PMC7885457          DOI: 10.1186/s13756-021-00903-0

Source DB:  PubMed          Journal:  Antimicrob Resist Infect Control        ISSN: 2047-2994            Impact factor:   4.887


  5 in total

1.  Antibiotic Changes Host Susceptibility to Eimeria falciformis Infection Associated with Alteration of Gut Microbiota.

Authors:  Yujiao Gong; Xianyong Liu; Sixin Zhang; Xinming Tang; Jun Zou; Xun Suo
Journal:  Infect Immun       Date:  2022-08-30       Impact factor: 3.609

2.  The Gut Microbiota: Master of Puppets Connecting the Epidemiology of Infectious, Autoimmune, and Metabolic Disease.

Authors:  Olaf F A Larsen; Maike van der Grint; Cato Wiegers; Linda H M van de Burgwal
Journal:  Front Microbiol       Date:  2022-04-29       Impact factor: 6.064

3.  Acinetobacter calcoaceticus is Well Adapted to Withstand Intestinal Stressors and Modulate the Gut Epithelium.

Authors:  Janiece S Glover; Brittney D Browning; Taylor D Ticer; Amy C Engevik; Melinda A Engevik
Journal:  Front Physiol       Date:  2022-05-24       Impact factor: 4.755

Review 4.  Bioengineered Probiotics: Synthetic Biology Can Provide Live Cell Therapeutics for the Treatment of Foodborne Diseases.

Authors:  Karla Cristina P Cruz; Laura O Enekegho; David T Stuart
Journal:  Front Bioeng Biotechnol       Date:  2022-05-17

Review 5.  Host factors facilitating SARS-CoV-2 virus infection and replication in the lungs.

Authors:  Sébastien Boutin; Dagmar Hildebrand; Steeve Boulant; Michael Kreuter; Jule Rüter; Srinivas Reddy Pallerla; Thirumalaisamy P Velavan; Dennis Nurjadi
Journal:  Cell Mol Life Sci       Date:  2021-07-05       Impact factor: 9.261

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.